Ultrarare missense and frameshift variants in the *TECTA* gene may involve tectorial membrane in familial Meniere disease

Pablo Román-Naranjo^{1,2,3,4}, Alberto M. Parra-Perez^{1,3,4}, Alba Escalera-Balsera^{1,2,3}, Andrés Soto-Varela^{5,6}, Alvaro Gallego-Martinez^{1,2,3}, Ismael Aran⁷, Nicolas Perez-Fernandez⁸, David Bächinger⁹, Andreas H. Eckhard⁹, Rocio Gonzalez-Aguado¹⁰, Lidia Frejo^{1,2,3}, Jose A. Lopez-Escamez^{1,2,3,4}

Affiliations

- 1 Otolology & Neurotology Group CTS 495, Department of Genomic Medicine, GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de la Ilustración, 114, 18016 Granada, Spain
- 2 Sensorineural Pathology Programme, Centro de Investigación Biomédica en Red en Enfermedades Raras, CIBERER, 28029 Madrid, Spain
- 3 Department of Otolaryngology, Instituto de Investigación Biosanitaria ibs.Granada, Hospital Universitario Virgen de las Nieves, Universidad de Granada, 18014 Granada, Spain
- 4 Division of Otolaryngology, Department of Surgery, University of Granada, 18011 Granada, Spain
- 5 Division of Otoneurology, Department of Otorhinolaryngology, Complejo Hospitalario Universitario, Santiago de Compostela, Spain
- 6 Department of Surgery and Medical-Surgical Specialities, Universidade de Santiago de Compostela, Spain.
- 7 Department of Otolaryngology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain
- 8 Department of Otorhinolaryngology, Clinica Universidad de Navarra, Madrid, Spain
- 9 Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.
- 10 Department of Otorhinolaryngology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

* Correspondence: pablo.roman@genyo.es; jalopezescamez@ugr.es; Tel.: +34-958-715-500 (Ext 160)

Acknowledgments

The authors appreciate the participation of all patients with MD and their families in this study.

This project was partially funded by H2020-SC1-2019-848261 (UNITI), CECEU PY20-00303 (EPIMEN), European Regional Funds B-CTS-68-UGR20 (M3N-OMIC) and the Schmieder-Bohrisch Foundation (Geneva, Switzerland). DB is supported by a national MD-PhD scholarship from the Swiss National Science Foundation (SNSF). AHE is supported by a career development grant ("Filling the Gap") from the University of Zurich, Switzerland.

ABSTRACT

Background: Meniere's disease (MD) is an inner ear disease defined by episodes of vertigo associated with sensorineural hearing loss initially affecting low- to medium frequencies, tinnitus, and aural fullness. Familial aggregation has been reported in 9-10% of MD patients showing, mostly, an autosomal dominant inheritance pattern with incomplete penetrance. However, familial MD is a genetically heterogeneous disorder and other inheritance patterns have been recently proposed, such as recessive and digenic inheritance involving rare variants in *OTOG* and *MYO7A* genes, respectively. In this study, a familial MD cohort was recruited to identify new candidate genes.

Methods: Exome sequencing was performed in 99 individuals (from 77 families) diagnosed with MD according to the diagnostic criteria defined by the Barany Society. Candidate variants were classified based on the ACMG/AMP guidelines, and their effects were evaluated by protein modeling. Standard audiometric evaluations were retrieved, and a case report was made of each family to assess the genotype-phenotype correlations.

Results: The *TECTA* gene, which encodes α -tectorin, was highlighted as a candidate for four multicasel MD families carrying rare missense heterozygous variants and a short deletion in this gene. Variants in α -tectorin were also found in two additional families with one MD patient and relatives with partial syndromes carrying a missense heterozygous variant and a short deletion. According to the predicted protein model, these variants could affect the stability of α -tectorin.

Conclusions: Several MD families were identified carrying rare variants and deletions in the *TECTA* gene, which encodes one of the main proteins of the tectorial membrane (TM). The TM is an extracellular matrix localized over the sensory epithelium mediating the mechanical stimulation of cochlear hair cells, a critical role in the process of hearing. Modifications on the TM stability and the micromechanics involved in the sound-evoked motion of stereocilia might be involved in familial MD.

Keywords: Genomics, Hearing loss, Inner ear, Meniere's disease, Vestibular disorders

BACKGROUND

The tectorial membrane (TM) is an extracellular matrix with a unique structure^{1,2} containing three different collagens and three non-collagenous glycoproteins expressed at high levels just in the inner ear: α -tectorin, β -tectorin, and otogelin³⁻⁶. Several roles have been suggested for the TM in hearing such as contributing to control of hearing sensitivity by influencing the ionic environment around the hair cell stereocilia⁷. Sound stimulates movement of the hair cells relative to the TM, deflects the stereocilia, and leads to oscillations in the hair cell membrane potential, transducing sound into electrical signals.

Alpha-tectorin (encoded by *TECTA*) is one of the main non-collagenous proteins of the TM, an extracellular matrix that lies over the stereocilia of the hair cells and it is critical for the deflection of the stereocilia and gating of mechanotransduction channels⁸. Mutations in this gene, located in 11q22-q24, are known to cause two phenotypes of non-syndromic autosomal hereditary hearing loss⁹: dominant (Deafness, Autosomal Dominant 8/12; DFNA8/12)¹⁰ and recessive (Deafness autosomal recessive 21; DFNB21)¹¹. To date, over 122 pathogenic or likely pathogenic variants have been identified in the *TECTA* gene that may cause non-syndromic hearing loss (NSHL), not being associated with any other symptoms (<http://deafnessvariationdatabase.org/>; Release: 4 Jan 2021; Accessed: 29 Oct 2021)¹².

DFNA8/12, first described in 1998 by Kirschhofer et al.⁸, showed an Austrian family in which 11 individuals covering 4 generations had autosomal dominant NSHL. It was defined by sensorineural hearing loss (SNHL) affecting a broad spectrum of frequencies depending on the domain in which the mutation occurs¹³ with a typical U-shaped audiogram. Its onset could be prelingual or in childhood and the progression of hearing loss can be stable or progressive. *TECTA* mutations are reported in up to 4% of all cases of autosomal dominant NSHL¹⁴.

Mustapha et al. (1999), described a Lebanese family belonging to the Shiite community in which 9 members presented with a prelingual severe-to-profound sensorineural isolated form of

deafness¹¹. DFNB21 is defined by a severe-to-profound prelingual hearing loss (70-110dB on all frequencies, most pronounced in mid-frequencies) with a cookie-bite or U-shape audiometric configuration¹⁵. Nonsense mutations that cause DFNB21 create premature stop codons that truncate the α -tectorin protein, leading to a non-functional version of the protein. A total loss of α -tectorin function alters the structure of the TM in such a way that sound cannot be converted to nerve impulses¹⁶.

Meniere disease (MD [OMIM 156000]) is an inner ear disorder with an estimated prevalence of 75/100,000 in the Southern European population¹⁷. It is defined by episodes of vertigo associated with SNHL, initially affecting low- to medium frequencies, tinnitus, and aural fullness¹⁸. Familial aggregation in MD has been described in 9-10% of European descendant population¹⁹. Most families show an autosomal dominant inheritance pattern and rare missense variants in several genes have been described in unrelated MD families^{20,21}. Nevertheless, none of these variants has been reported in other MD families, supporting genetic heterogeneity in familial MD. Recently in two different studies, enrichment of rare missense variants in the *OTOG* gene was found in 15 unrelated MD families²² and, in an exome sequencing study in 62 MD families, other 9 families showed rare heterozygous variants in the *MYO7A* gene associated with the MD phenotype²³.

Here, we have performed bioinformatic analyses in exome sequencing data obtained from 99 individuals (77 families with MD) and found 7 patients in 4 unrelated families with rare missense variants and a short deletion in the *TECTA* gene. Variants in this gene were also found in two additional families with one MD patient and relatives with partial syndromes carrying a missense heterozygous variant and a short deletion. We suggest that these deletions and missense variants in the *TECTA* gene could change the TM micromechanics involved in the sound-evoked motion of stereocilia in familial MD.

MATERIALS & METHODS

Ethics

This study protocol was approved by the local ethics committees (MS/2014/02, Institutional Review Board for Clinical Research, Universidad de Granada, Spain; KEK-ZH-Nr. 2019-01006, Kantonale Ethikkommission, Zurich, Switzerland) and a written informed consent to donate biological samples was obtained from all subjects. The study was carried out according to the principles of the Declaration of Helsinki revised in 2013 for investigation with human subjects.

Patient assessment, selection, and clinical phenotyping

MD patients were diagnosed and recruited from different Spanish hospitals within the Meniere's Disease Consortium (MeDiC). Patients were diagnosed according to the diagnostic criteria defined by the International Classification Committee for Vestibular Disorders of the Barany Society in 2015¹⁸. A complete audiological and vestibular assessment was performed, including magnetic resonance imaging in all cases, to rule out other vestibular diseases that could explain the phenotype. Pure-tone audiograms were retrieved to assess hearing loss since the onset of the disease. A total of 99 Spanish patients with familial MD over 18 years old from 77 different families were selected for exome sequencing.

DNA extraction and exome sequencing

Blood or saliva samples were collected to obtain DNA as previously described²⁴. DNA samples were extracted with QIAamp DNA Mini Kit (Qiagen, Venlo, The Netherlands) and prepIT-L2P (DNA Genotek, Ottawa, Canada), respectively, following the manufacturer's protocols. DNA concentration and quality parameters were checked by Nanodrop (ThermoFisher) and Qubit (Invitrogen) to assess that the samples reach the quality and concentration required for exome sequencing. Additionally, DNA integrity was verified by electrophoresis in a 2% agarose gel.

Exome sequencing was chosen for this study. All exomes were sequenced as previously described²³. Exome libraries and coding regions were selected using the Agilent SureSelect XT v6 Exome kit (Agilent Technologies, Santa Clara, CA, USA). Sequencing was performed in a NovaSeq 6000 platform (Illumina) with a mean coverage of 100X.

Processing and dataset generation

All sequenced samples were aligned using the GRCh38/Hg38 reference genome with the maximal exact matches algorithm from Burrows-Wheeler Aligner. For variant calling, we followed standard recommended criteria from GATK. Exome reference alignment, base quality score recalibration, variant calling, and quality filtering pipeline was addressed using Sarek Nextflow pipeline (NF-ACore)²⁵. Post-alignment processing was used to remove duplicated reads and the quality of the alignment itself was assessed²⁶, genetic variants were then called using the Haplotypecaller function from GATK. After the calling, we merged all the files to generate the MD variant dataset. We performed a variant quality filtering step using the variant quality score recalibration approach recommended by GATK. As a result, two variant call format files were generated, retrieving single nucleotide variants (SNVs) and short insertion and deletions from the sequenced exomes.

Annotation and prioritization strategy

To annotate the MD variant dataset, we used the Variant Effect Predictor (VEP, Ensembl). Then, we selected minor allele frequency (MAF) thresholds of 0.005 and 0.0005 to identify both autosomal-recessive and autosomal-dominant rare variants in the familial MD cohort, respectively, based on the data from a multi-ethnic study that assessed the pathogenicity of reported NSHL variants²⁷. Allelic frequencies were retrieved for the non-Finish European (NFE) population from the Exome Aggregation Consortium (ExAC; N=32,299) and the Genome

Aggregation Database (gnomAD; N=33,365) databases, and the Spanish population from the Collaborative Spanish Variant Server (CSVS; N=1,942) database²⁸. Candidate variants were then classified according to the American College of Medical Genetics (ACMG) and the Association for Molecular Pathology (AMP) guidelines²⁹, according to the specific guidelines for variant interpretation in genetic hearing loss³⁰. Additionally, *in-silico* tools such as Sorting Intolerant From Tolerant (SIFT; SIFT<0.05), Polymorphism Phenotyping (Polyphen; Polyphen>0.446), Genomic Evolutionary Rate Profiling (GERP; GERP>2) or Combined Annotated Dependent Depletion (CADD; CADD>15) were used to prioritize and classify each variant according to its predicted pathogenicity.

Lastly, as an additional variant prioritization method, candidate genes carrying rare variants were associated with mammalian phenotypes using the Mouse Genome Database (<http://www.informatics.jax.org>). Similarly, the Human Phenotype Ontology Project (<https://hpo.jax.org/app/>) and the Online Mendelian Inheritance in Man (OMIM; <https://omim.org/>) databases were used to determine associations in humans between candidate genes and phenotypes.

Statistical analysis

European and Spanish databases such as ExAC, gnomAD, and CSVS were used as references to compare the observed MAF in familial MD. Odds ratios with 95% confidence interval were calculated for each single or set of variants. One-side p-values were corrected for multiple testing following the Bonferroni approach. A corrected p-value < 0.05 was considered statistically significant. The same approach was followed to assess if a combination of variants showed a significant association.

Candidate variant validation and representation

Regions with prioritized variants were visually inspected using the Integrative Genome Viewer software. Novel variants were validated using Sanger sequencing. Primers used for PCR (Supplementary Table 1) were designed neighboring the regions flanking the variants using the Primer3 v4.1 (<http://bioinfo.ut.ee/primer3/>), Primer-Blast (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>), and the Oligoanalyzer tool (<https://eu.idtdna.com/calc/analyser/>). Candidate genes and variants were represented using Illustrator for Biological Sequences Version 1.0³¹.

Hearing assessment and analysis

To analyze the time course of the hearing profile in familial MD cases with candidate variants, standard audiometric evaluations for air and bone conduction prompted by pure tones from 125 to 8,000Hz were retrieved from their clinical records.

Alpha-tectorin protein model

The effect of candidate variants on the α -tectorin protein structure was evaluated by protein modeling. The human α -tectorin mature amino acid sequence (from 23 to 2,091) was retrieved from Uniprot entry O75443, containing 10 functional domains. Structural models of the domains were generated using MODELLER (homology modeling)³², Robetta-ab³³ (ab-initio modeling), and AlphaFold2³⁴ (ab-initio modeling) methods, and the best ones were assembled using the DEMO method³⁵. Each of the generated models and the final assembly were validated using the structure validation algorithms MolProbity³⁶, Verify3D³⁷, ERRAT³⁸, ProSA-Web³⁹, and QMEANDisCo⁴⁰. The *in-silico* model was used to predict the stability change ($\Delta\Delta G$) of the α -tectorin produced by the candidate variants. Hence, we used DynaMut2⁴¹, MAESTROweb⁴², mCSM⁴³, PremPS⁴⁴ and CUPSAT⁴⁵ tools. Variants were classified as neutral when $-0.5 < \Delta\Delta G < 0.5$ ⁴⁶. Finally, a prediction of Ca²⁺ ion binding sites was also performed to observe the possible effects of the variants on Ca²⁺ uptake with the metal ion-binding site prediction (MIB) method⁴⁷.

Variant data and protein structural model submission

All candidate variants in the *TECTA* gene have been submitted to the Clinvar database (<http://www.ncbi.nlm.nih.gov/clinvar/>). The accession numbers for these variants are as follow: SUB10993075, SUB10994469 and SUB10994413.

The α -tectorin structural model was submitted to the ModelArchive database (<https://modelarchive.org/doi/10.5452/ma-xd6ic>; Public access after publication. Temporary access code: mwnV7cphoi)

RESULTS

Rare missense variants and deletions in the TECTA gene in MD

A total of 34,833 and 20,684 nonsynonymous (missense, start-loss, stop-gain, and stop-loss) or splice-site variants were considered after using, respectively, MAF thresholds of 0.005 and 0.0005 in the familial MD cohort. These rare variants were found in 9,666 genes using the most restrictive MAF threshold and in 12,366 genes using the 0.005 MAF threshold.

After assessing and analyzing those genes with non-singleton variants (i.e., observed in more than one patient), and beyond the genes related to familial MD already published^{22,23}, the *TECTA* gene was highlighted as the candidate for 4 multicase MD families carrying rare missense heterozygous variants (F1 – F3) and a short deletion (F4) in this gene. Variants in this gene were also found in two additional families with one MD patient and relatives with partial syndromes carrying a missense heterozygous variant (F5) and a short deletion (F6) (Table 1).

The three variants in all multicase MD families were found clustered in the zonadhesin-like region, between the third trypsin inhibitor-like cysteine-rich (TIL) domain and the fourth von Willebrand factor type D (VWFD) domain. On the other hand, the two variants observed in the two families with partial syndromes were found close to the zona pellucida (Figure 1).

Of note, the variant chr11:121158016T>C (p.Val1494Ala) was found in F1, F2, and a sporadic case. The segregation of this variant was confirmed in F1, where it segregated in all three affected MD individuals and the father of III-7, who only suffered from hearing loss. The frequency of this variant in the NFE population from gnomAD is 8.8×10^{-5} and no individuals have been reported as homozygous for the alternate allele. This variant is predicted to impact the protein by several *in-silico* tools (GERP=3.09, PolyPhen=0.954, CADD=24.3) and it was classified as a variant of unknown significance (VUS). Interestingly, a rare variant in chr10:112298172A>C (p.Lys259Gln) in the *TECTB* was found in F2 along with the p.Val1494Ala *TECTA* variant. Moreover, a novel

frameshift deletion in chr11:121157956AC>A (p.Asn1474LysfsTer91) found in F4 was classified as likely pathogenic. This deletion resulted in a premature stop codon after 91 amino acids that generates a truncated protein of 1594 residues instead of 2155. The missense variant chr11:121152980G>C (p.Cys1402Ser) found in F3, whose frequency in the NFE population is 1.5×10^{-5} , was also predicted to impact the protein (SIFT=0, GERP=5.33, PolyPhen=0.993; CADD=28), and it was classified as VUS according to the ACMG/AMP guidelines.

The two additional variants observed in the families with partial syndromes were classified as VUS. The variant chr11:121165368C>T (p.Pro1790Ser) was found in F5 segregating in two patients, the father with MD and his daughter with only vestibular symptoms. This is a novel variant not observed in gnomAD. Finally, the short deletion chr11:121189864GC>C (p.Gly2118ProfsTer22) observed in F6 results in a premature stop codon at position 2139, generating a slightly shorter protein. This variant has been observed in only one individual (African/African American population) from gnomAD.

Clinical description of families carrying variants in the TECTA gene

A briefcase report was made of each family to assess the genotype-phenotype correlations. Figures 2 and 3 show the pedigrees and the pure-tone audiograms, respectively, of the six families included in this study. Supplementary Table 2 shows a summary of the clinical information of familial MD patients carrying variants in the *TECTA* gene.

Family 1 (F1)

A family consisting of three women in two generations with the complete phenotype was selected for exome sequencing. In this family, six relatives had incomplete phenotypes: five relatives (four women and one man) with recurrent vertigo and one man with SNHL. Additionally, three relatives (two women and one man) also suffered from migraine.

The index case (III-11) was a woman suffering from right SNHL with episodes of vertigo since her 40s. However, in few years, the hearing loss evolved to bilateral SNHL. Her parent (II-6), who is currently in her 80s, was diagnosed with left-sided MD when she was 46-50 years old. The last time she was examined the patient presented bilateral hearing loss with a normal gain in the video head impulse test (vHIT). Finally, the relative III-7 was diagnosed with bilateral MD. Currently, III-7 is 51-55 years old and, when she was evaluated, she did not show hearing nor vestibular symptoms, showing normal hearing and vestibulo-ocular reflexes.

Family 2 (F2)

This family consists of two female cousins with MD in one generation (III-2 and III-6) where only III-6 (index patient) was available for exome sequencing. III-6 is in her 70s and suffers from unilateral (left ear) hearing loss since she was 51-55. The disease progressed from unilateral to bilateral MD when she was 61-65 years old, suffering from that moment mainly vestibular symptoms. Some of her relatives had partial syndromes: her parent (II-6) suffered from tinnitus, a trait that is also present in her child (IV-4). In addition, one of her relatives (II-8) presented SNHL and vertigo episodes who did not meet the diagnostic criteria for MD.

Family 3 (F3)

The third family consists of two relatives with MD, the parent (I-2) and her child (II-3), only being available for exome sequencing II-3. There are no intermediate phenotypes in this family, neither hearing loss, nor vertigo or tinnitus. Two relatives of II-3 have a history of high blood pressure. Additionally, one of them was diagnosed with cardiac valvulopathy and the other with psoriasis.

The index case (II-3) is a woman currently in her 50s suffering from fluctuating hearing loss and tinnitus in her right ear since she was 41-46. She experienced her first vertigo episode associated with fluctuating hearing loss at 45 years old. During the next 5 months, she suffered from 8 episodes of vertigo, 4 of them lasting more than two hours. Right canal paresis (62%) was

evidenced by bithermal caloric testing. The patient started treatment with acetazolamide (250-500 mg daily) without any improvement in her symptoms. Next, two intratympanic instillations of dexamethasone (23mg/ml) were administered in the right ear, with an improvement in control of vertigo. In a 10-year-follow-up, this patient suffered from 4 episodes of vertigo. Her parent (I-2) suffered from left-sided MD, but it progressed from unilateral to bilateral MD with severe hearing loss at the end of the disease. This patient used a combination of trimetazidine and vestibular sedatives to control vertigo attacks.

Family 4 (F4)

A fourth family consisting of two relatives with MD in two generations (parent and child) was studied. Only the child (II-1, index patient) was available for exome sequencing. Her parent, who died at the age of 36-40, suffered from unilateral MD since her thirties.

II-1 is currently a woman in her 80s suffering from bilateral MD. At the age of 21-25, the disease started as unilateral, affecting her right ear. We could not assess the hearing loss progression in this ear since the first audiogram we could recover was when the patient already suffered from severe SNHL affecting all frequencies. Over the years, the disease progressed affecting both ears, estimating the onset of the left hearing loss between the ages of 40 and 50. Hearing loss progressed in both ears showing a flat-type audiogram in her 70s. The vestibular assessment was performed at 76-80 year old by vHIT testing, showing a bilateral vestibular hypofunction. Due to a tympanostomy tube, caloric testing could not be performed. In this same year, the patient got a cochlear implant in her right ear.

Family 5 (F5)

A family consisting of a man with MD (II-3; index patient) and his child (III-1) with partial syndromes. II-3 is a man in his 70s suffering from bilateral MD since he was 31-35. We could not evaluate the hearing progression on this patient since the first audiogram we were able to retrieve

was when he was 61-65 and the disease had progressed for more than 30 years. At that time, hearing loss was already affecting all frequencies in both ears. His child, currently in her 50s, reported episodes of vertigo accompanied by tinnitus and headache during the last 5 years. However, she did not show a hearing loss. None of the other relatives reported MD nor partial syndromes: II-1 and III-2 suffered from high blood pressure and II-2 suffered from diabetes mellitus type 2.

Family 6 (F6)

The last family consisted of a woman with MD (IV-3) and two other relatives with partial syndromes (a woman (I-1) and a man (II-7)). The index patient (IV-3) is a woman in her 50s suffering from recurrent vertigo associated with tinnitus and aural fullness (left ear) since she was 26-30. This patient suffers from profound unilateral hearing loss affecting all frequencies since the first years of the disease. According to the familial pedigree, these traits (i.e., hearing loss or vertigo) were exclusively identified on the maternal side of the proband: her relative I-2 suffered from unknown etiology hearing loss and vertigo and her relative II-7 only suffered from hearing loss.

Sporadic patient

We have also identified a patient (woman; 71-75 years old) with sporadic MD carrying the same missense variant in the *TECTA* gene as F1 and F2 patients. This patient reported her first episode of vertigo when she was 61-65, when she had two prolonged episodes of vertigo, referring to a sensation of spinning motion, right-sided hearing loss, and vegetative symptoms. One week after her second vertigo episode, the audiogram showed normal thresholds except for a slight drop in high frequencies.

Few years later, the patient returned to the hospital reporting a new episode of vertigo, beginning with a sensation of spinning motion followed by tinnitus and hearing loss in her right ear. At that time, the audiogram showed a moderate to severe SNHL in her right ear involving all frequencies.

During that year, the patient reported new episodes of vertigo. Caloric testing was conducted, showing normal results. Vertigo attacks were controlled with steroids and betahistine.

When she was 71-75, the patient reported multiple episodes of vertigo lasting several hours with worsening hearing loss and aural fullness. The patient followed her treatment of betahistine and a salt-reduced diet was recommended. During the last years, the patient has not reported any vestibular symptoms, although she has referred tinnitus in her right ear.

Protein modeling

The α -tectorin protein model was obtained by modeling the protein domains using the AlphaFold2 method and assembled with the DEMO method (Figure 4). According to the geometrical validation results (Supplementary Table 3), we have obtained a reliable model compared to structures solved by experimental techniques at the geometric level. This model was used to predict the impact of SNVs on protein stability and Ca^{2+} binding sites.

p.Cys1402Ser (Cys1380Ser, in the mature protein without the signal peptide and the final propeptide), p.Val1494Ala (Val1472Ala), and p.Pro1790Ser (Pro1768Ser) variants were predicted *in-silico* to change the overall stability of the α -tectorin (Supplementary Table 5). Consistent with the used methods, variants p.Cys1402Ser found in F3 and p.Val1494Ala found in F1 and F2 were classified as destabilizing variants. In contrast, most of the used predictors classified the novel variant p.Pro1790Ser found in F5 as a neutral variant according to the predicted perturbation on protein stability. Four probable Ca^{2+} binding sites were predicted in the α -tectorin VWFD domain where the p.Pro1790Ser is located, however, this variant appears to not affect them (Supplementary Table 4 and Supplementary Figure 2).

DISCUSSION

Our findings support those rare variations in the *TECTA* gene may affect the stability of the protein α -tectorin in patients with familial MD suggesting a novel mechanism involving the TM in MD. The TM is an acellular structure that covers the sensory epithelium of the cochlea in the organ of Corti. This membrane, which is composed of a mixture of collagenous and non-collagenous proteins, plays a critical role in the process of hearing mediating the mechanical stimulation of cochlear hair cells⁴⁸. Thus, variants in these non-collagenous proteins of the TM, namely otogelin (*OTOG*), otogelin-like (*OTOGL*), α -tectorin (*TECTA*), β -tectorin (*TECTB*), and the carcinoembryonic antigen cell adhesion molecule 16 (*CEACAM16*), may result in different types of autosomal dominant or autosomal recessive hearing loss in humans: DFNB18B⁴⁹, DFNB84B⁵⁰, DFNA8/12¹⁰, DNFB21¹¹, DFNA4B⁵¹ or DFNB113⁵². In this study, we have identified 3 rare missense variants and 2 deletions in the *TECTA* gene in 4 multicase MD families and 2 families with MD and partial syndromes by exome sequencing. Of note, one of these rare variants (p.Val1494Ala) was found in two unrelated families segregating the MD phenotype, and two deletions generating a truncated form of the α -tectorin protein in other two families. These variants in α -tectorin could change the TM stability, disturbing the sound-evoked motion of hair cell stereocilia in familial MD.

Familial aggregation is reported in 9-10% of MD patients showing, mostly, an autosomal dominant inheritance pattern¹⁹. However, other inheritance patterns have been recently proposed involving rare variants in *OTOG* and *MYO7A* genes. Enrichment of rare variants was found in the *OTOG* gene in 15 families with MD, suggesting a recessive inheritance pattern mediated by compound heterozygous variants in this gene²². The *OTOG* gene encodes otogelin, an extracellular protein that participates in the otolith tethering in the otolithic membrane, the TM attachment crowns, and the horizontal top connectors between stereocilia^{6,53}. On the other hand, it was suggested a potential digenic inheritance pattern in familial MD mediated by rare missense variants in *MYO7A* and other genes encoding for proteins involved in the organization of the stereocilia links (e.g.,

CDH23, *PCDH15*, or *ADGRV1*)²³. The *MYO7A* gene encodes the myosin VIIA protein, a motor protein involved in the formation of ankle links and tips links in the stereocilia of hair cells⁵⁴. These two genes, *OTOG* and *MYO7A*, are closely related to the *TECTA* gene since they are highly expressed in the hair cell stereocilia and involved in the interaction with the TM. Rare variants in any of these genes could reduce the stability of the stereocilia proteins, the attachments of the apical crowns of the stereocilia to the TM or generate structural changes in the TM. This may lead to a sudden onset of spontaneous oscillations in a subset of hair bundles, resulting in a spurious signal that may cause abnormal depolarization of hair cells and fluctuation in hearing in MD.

The *TECTA* gene encodes the α -tectorin protein, one of the major non-collagenous proteins of the TM⁴⁸. This large protein contains 10 functional domains divided into three major regions: 1) an entactin-like (NIDO) region; 2) a larger middle region, the zonadhesin region containing a von Willebrand factor type C (VWFC) domain, four VWFD domains, and three TIL domains; and 3) the zona pellucida region⁵. Although there is little evidence, several molecular models involving α -tectorin, β -tectorin, and CEACAM16 have been proposed for the formation of the striated-sheet matrix, strands of filaments that organize the collagen fibers in the TM^{55,56}. Both, α - and β -tectorin contain a ZP region, a polymerization domain that could mediate the formation of either homomeric or heteromeric filaments crosslinked by CEACAM16. Studies in mice lacking functional *TECTA* (*Tecta* ^{Δ ENT/ Δ ENT}) showed a TM absent of striated-sheet matrix and completely detached from the organ of Corti¹⁶. Furthermore, several models carrying heterozygous variants in different *Tecta* domains were generated as models from human *TECTA* variants. These variants disrupted the structure of the covernet fibrils, the marginal band, the Hensen's stripe, and the Kimura's membrane^{57,58}. The structural consequences of variants in the *TECTA* gene showed in this study are expected to be milder compared to the phenotype showed in the *Tecta* ^{Δ ENT/ Δ ENT} mice model, resembling more the phenotypes exhibited by those mice models carrying heterozygous variants in *Tecta*.

The SNVs described in this study were investigated at the functional level according to the predicted α -tectorin protein model. The variant p.Val1494Ala was found in F1, F2 and a sporadic case of our sporadic MD cohort, being classified as VUS according to the ACMG/AMP criteria. Although this variant was located in the VWFD domain, a domain that can bind Ca^{2+} , the variant p.Val1494Ala seems to have no effect in the Ca^{2+} binding sites predicted using the protein model structure. In addition, based on the protein stability predictors, this variant produces a slightly destabilizing effect on α -tectorin. The missense variant p.Cys1402Ser found in F3 was classified as a VUS according to the ACMG/AMP guidelines. The change of cysteine to serine at residue 1402 can lead to the breaking of the Cys1359-Cys1402 disulfide bond. The suggested disulfide bond disruption could destabilize the striated-sheet matrix structure of the TM, causing progressive hearing loss⁵⁹.

In addition, a novel frameshift deletion p.Asn1474LysfsTer91 was found in F4, resulting in the absence of the fourth VWFD domain and the ZP domain. ZP and VWFD domains have been suggested to be involved in the TM matrix assembly through the formation of homomeric filaments of α -tectorin or heteromeric filaments with β -tectorin^{5,60}. In addition, the TM has been suggested as a reservoir for Ca^{2+} cations, which are needed to control the mechanotransduction channel in the stereocilia of hair cells⁷. Apparently, behind this function are the VFWD domains of α -tectorin and otogelin proteins, which can bind Ca^{2+} ions⁶¹. Thus, the short deletion found in F4 could potentially decrease Ca^{2+} uptake by the VWFD domain and prevent the formation of α -tectorin homodimers and α -tectorin/ β -tectorin heterodimers.

Rare variants in the *TECTA* gene were also detected in two families with MD and partial syndromes. The novel variant p.Pro1790Ser in F5 was classified as a neutral variant in terms of protein stability perturbation by 4 out of 6 prediction tools. Nevertheless, we cannot discard a deleterious effect of this variant for a reason different from stability. In fact, this variant, which affects the ZA-ZP interdomain of α -tectorin, is only one amino acid residue downstream of the

p.Pro1791Arg variant, firstly described by Hildebrand *et al.* in an American family suffering from prelingual mid-frequency SNHL¹⁴. Later, this variant was also found in a man suffering from progressive, postlingual SNHL⁶². Finally, although the p.Gly2118ProfsTer22 found in F6 occurs in the last exon, which is part of the α -tectorin propeptide, this region contains elements essential for its function. The α -tectorin suffers a post-translational modification in which it is tethered to the membrane via glycosylphosphatidylinositol (GPI), a process that seems to be needed to prevent the diffusion of secreted TM component. The C-terminal, region where the short deletion found in F6 is located, contains the GPI anchorage signal⁶³. As a result, this frameshift deletion could be involved in an alteration of the TM during its formation by the modification of the GPI anchorage signal and leading to the clinical phenotype.

The phenotype observed in the six families carrying rare heterozygous variants in the *TECTA* gene was described. In general, we observed a trend towards postlingual hearing loss worsening with age involving all frequencies. Conversely, we did not identify a different audiometric profile according to the region where the variants were localized, nor the cookie-bite/U-shaped audiogram typically observed in patients carrying recessive mutations in *TECTA*^{9,15,64}. Interestingly, the patients carrying frameshift deletions in this study (i.e., F4 & F6) presented an earlier age of onset compared to those patients carrying rare missense variants, suggesting a more significant alteration in the TM matrix that could correlate to an earlier occurrence of the phenotype.

Unlike the hearing loss phenotype, the association between variants in the *TECTA* gene and vestibular dysfunction has not been established since most patients carrying variants in α -tectorin do not show a vestibular phenotype. Nevertheless, some of these patients reported episodic vertigo or showed vestibular hyporeflexia^{60,65,66}. Furthermore, the expression of α -tectorin in the vestibular system has been demonstrated in several mouse models, being detected in the saccule and the utricle⁶⁷. Mice lacking α -tectorin showed reduced otoconial membranes with no obvious

behavioral defects¹⁶. In addition, a mechanism for otolith tethering requiring otogelin and α -tectorin has been proposed in a zebrafish model⁵³. In humans, Calzada *et al.* found that all patients who experienced drop attacks showed disrupted utricular otolithic membranes. Additionally, they showed that the average thickness of the utricular otolithic membrane in patients with MD was 11.45 micrometers, while in normal tissue the mean thickness was 38 micrometers⁶⁸. This reduced thickness in the otolithic membrane could be associated with changes in the structure of the proteins involved in the otolithic membrane, including α -tectorin. Nevertheless, since the role of α -tectorin in the human vestibular system is not completely clear, we cannot discard other genes or epigenetic factors that could modulate the vestibular phenotype in MD patients.

The results achieved in this study seem to be in line with the results obtained in most recent genetic studies about familial MD, where rare variants in *MYO7A* and *OTOG* gene were suggested to modify the stability or the interactions of different proteins in the apical surface of the sensory epithelia, such as hair cells (stereocilia) or the TM^{22,23}. In this study, the presence of rare missense variants and frameshift deletions in the *TECTA* gene in six unrelated families with MD suggests a role of this gene in the pathophysiology of the disease. However, because of the lack of a reliable association between α -tectorin and the vestibular function, we consider that additional variants and genes may contribute to the vestibular phenotype in MD.

DATA AVAILABILITY

The data that support the findings of this study are available from the corresponding author upon reasonable request.

LIST OF ABBREVIATIONS

$\Delta\Delta G$: Stability change

ACMG: American College of Medical Genetics

AMP: Association for Molecular Pathology

CADD: Combined Annotated Dependent Depletion

CSVS: Collaborative Spanish Variant Server

ExAC: Exome Aggregation Consortium

GERP: Genomic Evolutionary Rate Profiling

gnomAD: Genome Aggregation Database

GPI: Glycosylphosphatidylinositol

MAF: Minor allele frequency

MD: Meniere's disease

MeDiC: Meniere's Disease Consortium

MIB: Metal ion-binding site prediction

NFE: Non-Finish European

NSHL: Non-syndromic hearing loss

Polyphen: Polymorphism Phenotyping

SIFT: Sorting Intolerant From Tolerant

SNHL: Sensorineural hearing loss

SNVs: Single nucleotide variants

TIL: Trypsin Inhibitor like cysteine-rich

TM: Tectorial membrane

VEP: Variant Effect Predictor

vHIT: video head impulse test

VWFC: von Willebrand factor type C

VWFD: von Willebrand factor type D

ZP: Zona-pellucida

REFERENCES

1. Lim DJ. Functional structure of the organ of Corti: a review. *Hear Res.* 1986;22:117-146. doi:10.1016/0378-5955(86)90089-4
2. Hasko JA, Richardson GP. The ultrastructural organization and properties of the mouse tectorial membrane matrix. *Hear Res.* 1988;35(1):21-38. doi:10.1016/0378-5955(88)90037-8
3. Richardson GP, Russell IJ, Duance VC, Bailey AJ. Polypeptide composition of the mammalian tectorial membrane. *Hear Res.* 1987;25(1):45-60. doi:10.1016/0378-5955(87)90078-5
4. Thalmann I, Thallinger G, Crouch EC, Comegys TH, Barrett N, Thalmann R. Composition and supramolecular organization of the tectorial membrane. *The Laryngoscope.* 1987;97(3 Pt 1):357-367.
5. Legan PK, Rau A, Keen JN, Richardson GP. The mouse tectorins. Modular matrix proteins of the inner ear homologous to components of the sperm-egg adhesion system. *J Biol Chem.* 1997;272(13):8791-8801. doi:10.1074/jbc.272.13.8791
6. Cohen-Salmon M, El-Amraoui A, Leibovici M, Petit C. Otogelin: A glycoprotein specific to the acellular membranes of the inner ear. *Proc Natl Acad Sci U S A.* 1997;94(26):14450-14455.
7. Strimbu CE, Prasad S, Hakizimana P, Fridberger A. Control of hearing sensitivity by tectorial membrane calcium. *Proc Natl Acad Sci U S A.* 2019;116(12):5756-5764. doi:10.1073/pnas.1805223116
8. Kirschhofer K, Kenyon JB, Hoover DM, et al. Autosomal-dominant, prelingual, nonprogressive sensorineural hearing loss: localization of the gene (DFNA8) to chromosome 11q by linkage in an Austrian family. *Cytogenet Cell Genet.* 1998;82(1-2):126-130. doi:10.1159/000015086
9. Balciuniene J, Dahl N, Jalonen P, et al. Alpha-tectorin involvement in hearing disabilities: one gene--two phenotypes. *Hum Genet.* 1999;105(3):211-216. doi:10.1007/s004390051091
10. Verhoeven K, Van Laer L, Kirschhofer K, et al. Mutations in the human alpha-tectorin gene cause autosomal dominant non-syndromic hearing impairment. *Nat Genet.* 1998;19(1):60-62. doi:10.1038/ng0598-60
11. Mustapha M, Weil D, Chardenoux S, et al. An alpha-tectorin gene defect causes a newly identified autosomal recessive form of sensorineural pre-lingual non-syndromic deafness, DFNB21. *Hum Mol Genet.* 1999;8(3):409-412. doi:10.1093/hmg/8.3.409
12. Azaiez H, Booth KT, Ephraim SS, et al. Genomic Landscape and Mutational Signatures of Deafness-Associated Genes. *Am J Hum Genet.* 2018;103(4):484-497. doi:10.1016/j.ajhg.2018.08.006

13. Sagong B, Park R, Kim YH, et al. Two novel missense mutations in the TECTA gene in Korean families with autosomal dominant nonsyndromic hearing loss. *Ann Clin Lab Sci*. 2010;40(4):380-385.
14. Hildebrand MS, Morín M, Meyer NC, et al. DFNA8/12 caused by TECTA mutations is the most identified subtype of nonsyndromic autosomal dominant hearing loss. *Hum Mutat*. 2011;32(7):825-834. doi:10.1002/humu.21512
15. Naz S, Alasti F, Mowjoodi A, et al. Distinctive audiometric profile associated with DFNB21 alleles of TECTA. *J Med Genet*. 2003;40(5):360-363. doi:10.1136/jmg.40.5.360
16. Legan PK, Lukashkina VA, Goodyear RJ, Kössi M, Russell IJ, Richardson GP. A targeted deletion in alpha-tectorin reveals that the tectorial membrane is required for the gain and timing of cochlear feedback. *Neuron*. 2000;28(1):273-285. doi:10.1016/s0896-6273(00)00102-1
17. Morales Angulo C, Gómez Castellanos R, García Mantilla J, Bezos Capelastegui JT, Carrera F. Epidemiología de la enfermedad de meniere en cantabria. *Acta Otorrinolaringológica Esp*. 2003;54(9):601-605. doi:10.1016/S0001-6519(03)78456-8
18. Lopez-Escamez JA, Carey J, Chung WH, et al. Diagnostic criteria for Menière's disease. *J Vestib Res Equilib Orientat*. 2015;25(1):1-7. doi:10.3233/VES-150549
19. Requena T, Espinosa-Sanchez JM, Cabrera S, et al. Familial clustering and genetic heterogeneity in Meniere's disease. *Clin Genet*. 2014;85(3):245-252. doi:10.1111/cge.12150
20. Escalera-Balsera A, Roman-Naranjo P, Lopez-Escamez JA. Systematic Review of Sequencing Studies and Gene Expression Profiling in Familial Meniere Disease. *Genes*. 2020;11(12):E1414. doi:10.3390/genes11121414
21. Gallego-Martinez A, Lopez-Escamez JA. Genetic architecture of Meniere's disease. *Hear Res*. 2020;397:107872. doi:10.1016/j.heares.2019.107872
22. Roman-Naranjo P, Gallego-Martinez A, Soto-Varela A, et al. Burden of Rare Variants in the OTOG Gene in Familial Meniere's Disease. *Ear Hear*. 2020;41(6):1598-1605. doi:10.1097/AUD.0000000000000878
23. Roman-Naranjo P, Moleon MDC, Aran I, et al. Rare coding variants involving MYO7A and other genes encoding stereocilia link proteins in familial meniere disease. *Hear Res*. 2021;409:108329. doi:10.1016/j.heares.2021.108329
24. Szczepek AJ, Frejo L, Vona B, et al. Recommendations on Collecting and Storing Samples for Genetic Studies in Hearing and Tinnitus Research. *Ear Hear*. 2019;40(2):219-226. doi:10.1097/AUD.0000000000000614
25. Garcia M, Juhos S, Larsson M, et al. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. *F1000Research*. 2020;9:63. doi:10.12688/f1000research.16665.2

26. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 2010;20(9):1297-1303. doi:10.1101/gr.107524.110
27. Shearer AE, Eppsteiner RW, Booth KT, et al. Utilizing ethnic-specific differences in minor allele frequency to recategorize reported pathogenic deafness variants. *Am J Hum Genet.* 2014;95(4):445-453. doi:10.1016/j.ajhg.2014.09.001
28. Peña-Chilet M, Roldán G, Perez-Florido J, et al. CSVS, a crowdsourcing database of the Spanish population genetic variability. *Nucleic Acids Res.* 2021;49(D1):D1130-D1137. doi:10.1093/nar/gkaa794
29. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med Off J Am Coll Med Genet.* 2015;17(5):405-424. doi:10.1038/gim.2015.30
30. Oza AM, DiStefano MT, Hemphill SE, et al. Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss. *Hum Mutat.* 2018;39(11):1593-1613. doi:10.1002/humu.23630
31. Liu W, Xie Y, Ma J, et al. IBS: an illustrator for the presentation and visualization of biological sequences. *Bioinforma Oxf Engl.* 2015;31(20):3359-3361. doi:10.1093/bioinformatics/btv362
32. Webb B, Sali A. Protein Structure Modeling with MODELLER. *Methods Mol Biol Clifton NJ.* 2021;2199:239-255. doi:10.1007/978-1-0716-0892-0_14
33. Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. *Nucleic Acids Res.* 2004;32(Web Server issue):W526-531. doi:10.1093/nar/gkh468
34. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. *Nature.* 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2
35. Zhou X, Hu J, Zhang C, Zhang G, Zhang Y. Assembling multidomain protein structures through analogous global structural alignments. *Proc Natl Acad Sci U S A.* 2019;116(32):15930-15938. doi:10.1073/pnas.1905068116
36. Williams CJ, Headd JJ, Moriarty NW, et al. MolProbity: More and better reference data for improved all-atom structure validation. *Protein Sci Publ Protein Soc.* 2018;27(1):293-315. doi:10.1002/pro.3330
37. Eisenberg D, Lüthy R, Bowie JU. VERIFY3D: assessment of protein models with three-dimensional profiles. *Methods Enzymol.* 1997;277:396-404. doi:10.1016/s0076-6879(97)77022-8
38. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. *Protein Sci Publ Protein Soc.* 1993;2(9):1511-1519. doi:10.1002/pro.5560020916

39. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res.* 2007;35(Web Server issue):W407-410. doi:10.1093/nar/gkm290
40. Studer G, Rempfer C, Waterhouse AM, Gumieny R, Haas J, Schwede T. QMEANDisCo-distance constraints applied on model quality estimation. *Bioinforma Oxf Engl.* 2020;36(6):1765-1771. doi:10.1093/bioinformatics/btz828
41. Rodrigues CHM, Pires DEV, Ascher DB. DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations. *Protein Sci Publ Protein Soc.* 2021;30(1):60-69. doi:10.1002/pro.3942
42. Laimer J, Hiebl-Flach J, Lengauer D, Lackner P. MAESTROweb: a web server for structure-based protein stability prediction. *Bioinforma Oxf Engl.* 2016;32(9):1414-1416. doi:10.1093/bioinformatics/btv769
43. Pires DEV, Ascher DB, Blundell TL. mCSM: predicting the effects of mutations in proteins using graph-based signatures. *Bioinformatics.* 2014;30(3):335-342. doi:10.1093/bioinformatics/btt691
44. Chen Y, Lu H, Zhang N, Zhu Z, Wang S, Li M. PremPS: Predicting the impact of missense mutations on protein stability. *PLoS Comput Biol.* 2020;16(12):e1008543. doi:10.1371/journal.pcbi.1008543
45. Parthiban V, Gromiha MM, Schomburg D. CUPSAT: prediction of protein stability upon point mutations. *Nucleic Acids Res.* 2006;34(Web Server issue):W239-242. doi:10.1093/nar/gkl190
46. Pancotti C, Benevenuto S, Birolo G, et al. Predicting protein stability changes upon single-point mutation: a thorough comparison of the available tools on a new dataset. *Brief Bioinform.* Published online January 11, 2022:bbab555. doi:10.1093/bib/bbab555
47. Lin YF, Cheng CW, Shih CS, Hwang JK, Yu CS, Lu CH. MIB: Metal Ion-Binding Site Prediction and Docking Server. *J Chem Inf Model.* 2016;56(12):2287-2291. doi:10.1021/acs.jcim.6b00407
48. Goodyear RJ, Richardson GP. Structure, Function, and Development of the Tectorial Membrane: An Extracellular Matrix Essential for Hearing. *Curr Top Dev Biol.* 2018;130:217-244. doi:10.1016/bs.ctdb.2018.02.006
49. Schraders M, Ruiz-Palmero L, Kalay E, et al. Mutations of the Gene Encoding Otogelin Are a Cause of Autosomal-Recessive Nonsyndromic Moderate Hearing Impairment. *Am J Hum Genet.* 2012;91(5):883-889. doi:10.1016/j.ajhg.2012.09.012
50. Yariz KO, Duman D, Zazo Seco C, et al. Mutations in OTOGL, encoding the inner ear protein otogelin-like, cause moderate sensorineural hearing loss. *Am J Hum Genet.* 2012;91(5):872-882. doi:10.1016/j.ajhg.2012.09.011
51. Zheng J, Miller KK, Yang T, et al. Carcinoembryonic antigen-related cell adhesion molecule 16 interacts with alpha-tectorin and is mutated in autosomal dominant hearing

- loss (DFNA4). *Proc Natl Acad Sci U S A*. 2011;108(10):4218-4223. doi:10.1073/pnas.1005842108
52. Booth KT, Kahrizi K, Najmabadi H, Azaiez H, Smith RJ. Old gene, new phenotype: splice-altering variants in CEACAM16 cause recessive non-syndromic hearing impairment. *J Med Genet*. 2018;55(8):555-560. doi:10.1136/jmedgenet-2018-105349
53. Stooke-Vaughan GA, Obholzer ND, Baxendale S, Megason SG, Whitfield TT. Otolith tethering in the zebrafish otic vesicle requires Otogelin and α -Tectorin. *Dev Camb Engl*. 2015;142(6):1137-1145. doi:10.1242/dev.116632
54. Morgan CP, Krey JF, Grati M, et al. PDZD7-MYO7A complex identified in enriched stereocilia membranes. *eLife*. 2016;5:e18312. doi:10.7554/eLife.18312
55. Kammerer R, Rüttiger L, Riesenberger R, et al. Loss of mammal-specific tectorial membrane component carcinoembryonic antigen cell adhesion molecule 16 (CEACAM16) leads to hearing impairment at low and high frequencies. *J Biol Chem*. 2012;287(26):21584-21598. doi:10.1074/jbc.M111.320481
56. Cheatham MA, Goodyear RJ, Homma K, et al. Loss of the tectorial membrane protein CEACAM16 enhances spontaneous, stimulus-frequency, and transiently evoked otoacoustic emissions. *J Neurosci Off J Soc Neurosci*. 2014;34(31):10325-10338. doi:10.1523/JNEUROSCI.1256-14.2014
57. Xia A, Gao SS, Yuan T, et al. Deficient forward transduction and enhanced reverse transduction in the alpha tectorin C1509G human hearing loss mutation. *Dis Model Mech*. 2010;3(3-4):209-223. doi:10.1242/dmm.004135
58. Legan PK, Goodyear RJ, Morín M, et al. Three deaf mice: mouse models for TECTA-based human hereditary deafness reveal domain-specific structural phenotypes in the tectorial membrane. *Hum Mol Genet*. 2014;23(10):2551-2568. doi:10.1093/hmg/ddt646
59. Richardson G, Lukashkin A, Russell I. The tectorial membrane: One slice of a complex cochlear sandwich. *Curr Opin Otolaryngol Head Neck Surg*. 2008;16(5):458-464. doi:10.1097/MOO.0b013e32830e20c4
60. Alloisio N, Morlé L, Bozon M, et al. Mutation in the zonadhesin-like domain of alpha-tectorin associated with autosomal dominant non-syndromic hearing loss. *Eur J Hum Genet EJHG*. 1999;7(2):255-258. doi:10.1038/sj.ejhg.5200273
61. Huang RH, Wang Y, Roth R, et al. Assembly of Weibel–Palade body-like tubules from N-terminal domains of von Willebrand factor. *Proc Natl Acad Sci U S A*. 2008;105(2):482-487. doi:10.1073/pnas.0710079105
62. Yasukawa R, Moteki H, Nishio S ya, et al. The Prevalence and Clinical Characteristics of TECTA-Associated Autosomal Dominant Hearing Loss. *Genes*. 2019;10(10):744. doi:10.3390/genes10100744
63. Kim DK, Kim JA, Park J, Niazi A, Almishaal A, Park S. The release of surface-anchored α -tectorin, an apical extracellular matrix protein, mediates tectorial membrane organization. *Sci Adv*. 2019;5(11):eaay6300. doi:10.1126/sciadv.aay6300

64. Nam GS, Rim JH, Choi JY, et al. The TECTA mutation R1890C is identified as one of the causes of genetic hearing loss: a case report. *BMC Med Genet.* 2019;20(1):57. doi:10.1186/s12881-019-0775-1
65. Li Z, Guo Y, Lu Y, et al. Identification of a Novel TECTA mutation in a Chinese DFNA8/12 family with prelingual progressive sensorineural hearing impairment. *PloS One.* 2013;8(7):e70134. doi:10.1371/journal.pone.0070134
66. Ishikawa K, Naito T, Nishio SY, et al. A Japanese family showing high-frequency hearing loss with KCNQ4 and TECTA mutations. *Acta Otolaryngol (Stockh).* 2014;134(6):557-563. doi:10.3109/00016489.2014.890740
67. Rau A, Legan PK, Richardson GP. Tectorin mRNA expression is spatially and temporally restricted during mouse inner ear development. *J Comp Neurol.* 1999;405(2):271-280.
68. Calzada AP, Lopez IA, Ishiyama G, Ishiyama A. Otolithic Membrane Damage in Patients with Endolymphatic Hydrops and Drop Attacks. *Otol Neurotol Off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol.* 2012;33(9):1593-1598. doi:10.1097/MAO.0b013e318271c48b

TABLES

Table 1: Rare variants in the *TECTA* gene found in the studied familial MD cohort (N=99).

Location	Protein change	Info	Exon	Domain	MD family	gnomAD _{NFE} MAF	gnomAD _{MAX} MAF	ACMG
11:121158016T>C	p.Val1494Ala	Missense	14	VWFD 4	F1 & F2	8.8x10 ⁻⁵	9.7x10 ⁻⁵ (AFR)	VUS
11:121152980G>C	p.Cys1402Ser	Missense	13	TIL	F3	1.5x10 ⁻⁵	4.8x10 ⁻⁴ (OTH)	VUS
11:121157956AC>A	p.Asn1474LysfsTer91	Deletion	14	-	F4	Novel	Novel	LP
11:121165368C>T	p.Pro1790Ser	Missense	17	-	F5	Novel	Novel	VUS
11:121189864GC>C	p.Gly2118ProfsTer22	Deletion	23	-	F6	0	2.4x10 ⁻⁵ (AFR)	LP

Reference sequence: NM_005422.2 (*TECTA*); MAF: Minor allele frequency; NFE: Non-Finish European; MAX: Highest MAF value in gnomAD populations; ACMG: American College of Medical Genetics and Genomics; LP: Likely pathogenic; VUS: Variant of unknown significance

FIGURE LEGENDS

Figure 1: Variants distribution across the α -tectorin domains. The α -tectorin protein has several domains: the NIDO domain, the von Willebrand factor type C (VWFC: colored in green) and type D (VWFD) domains, the trypsin Inhibitor like cysteine rich (TIL) domain and the zona-pellucida (ZP) domains. Three rare missense variants (colored in blue) and two short deletions (colored in red) were found in four multicase MD families (arrow-shaped) and two additional families with one MD patient and relatives with partial syndromes (diamond-shaped). The position of stop codons generated by frameshift short deletions is indicated in red.

Figure 2: Serial pure tone audiograms for MD patients from the six families included in this study carrying variants in the *TECTA* gene. The different lines in the audiograms show the hearing loss progression across the years (yo). Years after onset are indicated in brackets for each individual.

Figure 3: Pedigrees of the six families carrying rare variants and short deletions in the *TECTA* gene.

Figure 4: Predicted effect of variants on the α -tectorin structure. A) Mature α -tectorin model showing the different domains that form the protein and the positions of the missense variants found in this study (indicated with black arrows). B) TIL-3 domain of WT α -tectorin (left) and C1402S mutant (right). A disulfide bridge between C1359 and C1402 is predicted in the WT protein (indicated with an arrow). This disulfide bridge disappears in the mutated protein, where appears a weak polar interaction between C1359 and S1402. C) VWF D-4 domain of WT α -tectorin (left) and V1494A mutant (right). D) Interdomain upstream the ZP domain of α -tectorin WT (left) and P1790S mutant (right). Yellow dashed lines represent polar interactions between residues within 4 Å from the mutated residue. Arrows show new or missing bonds. VWF D: Von Willebrand factor type D; ZP: Zona Pellucida.

Figure 1

Figure 2

Figure 3

Figure 4

SUPPLEMENTARY MATERIAL

Ultrarare missense and frameshift variants in the TECTA gene may involve tectorial membrane in familial Meniere disease

MEDRXIV

PABLO ROMAN-NARANJO, ALBERTO M. PARRA-PEREZ, ALBA ESCALERA-BALSERA, ANDRES SOTO-VARELA, ALVARO GALLEGOMARTINEZ, ISMAEL ARAN, NICOLAS PEREZ-FERNANDEZ, DAVID BÄCHINGER, ANDREAS H. ECKHARD, ROCIO GONZALEZ-AGUADO, LIDIA FREJO, JOSE ANTONIO LOPEZ-ESCAMEZ

SUPPLEMENTARY TABLES

Supplementary Table 1: Pair of primers used to validate candidate single nucleotide variants by Sanger Sequencing in the *TECTA* gene.

Variant (hg38)	Forward primer	Reverse primer
chr11:121152980G>C	TCACCTGCCCTCCAAACAG	CTCGTAATATTTGCCATCGGAGT
chr11:121165368C>T	CCATCTGACCATTTC AATGTGA	AAAAGGATGTAGCTGTACTTTGAAG
chr11:121158016T>C	ATGCAAGTCAGACGAGGAGT	AAGGAGATGTCGGGCAGTTT

Supplementary Table 2: Summary of the clinical information of familial MD patients carrying variants in the *TECTA* gene.

Families		F1	F2	F3	F4	F5	F6
Genetic variants	<i>TECTA</i> gene	p.Val1494Ala	p.Val1494Ala	p.Cys1402Ser	p.Asn1474LysfsTer91	p.Pro1790Ser	p.Gly2118ProfsTer22
MD patients	Index	III-11	III-6	II-3	II-1	II-3	III-2
	Other	II-6 III-7	III-2	I-2	I-2	-	-
Relatives with incomplete phenotype	Episodic vertigo	II-1, II-8, III-13, III-15, III-19	III-8	-	-	III-1	I-2
	Hearing loss	II-3	II-6, III-8	-	-	-	I-2, II-7
Clinical data of index patient	Sex	Female	Female	Female	Female	Male	Female
	Laterality (ear)	Unilateral (Right)	Bilateral	Unilateral (Right)	Bilateral	Bilateral	Unilateral (Left)
	Age of onset	41-45	51-55	41-45	21-25	31-25	26-30
	Autoimmune diseases	No	No	No	No	No	No

Supplementary Table 3. Predicted structural model evaluation of each of the α -tectorin domains, the 4-, 8-, and 10-domain assemblies of the protein using the DEMO method and the α -tectorin structural model predicted by AlphaFold2 (located at <https://alphafold.ebi.ac.uk/entry/O75443>). Molprobity Score, Verify3D, ERRAT, ProSA-web and QMEANDisCo metrics were used in the evaluation. Molprobity Score is a weighted logarithmic combination of different geometric scores such as clashscore, percentage of unfavoured Ramachandran and percentage of bad sidechain rotamers, giving a number that reflects the crystallographic resolution at which those values would be expected. Lower values of Molprobity Score are better. Verify3D determines the compatibility of an atomic model (3D) with its own amino acid sequence (1D) by assigning a structural type based on its location and environment. A higher score indicated high-quality of the structure. The overall quality factor, ERRAT, analyses the statistics of interactions between the different types of atoms and plots the value of the error function calculated by a comparison with highly refined structure statistics. As the generally accepted range for a high- quality model is >50, this analysis revealed that the backbone conformation and nonbonded interactions of all models were within the scope of a high-quality model. In the ProSA-web tool, the score is z-score defined as the energy separation between the native fold and the average of an ensemble of the misfolds in standard deviation units of the database. A z-score outside a range characteristic for native proteins of similar sizes indicated an erroneous structure. In this case, each model is in the range. Finally, QMEANDisCo evaluates the agreement of pairwise distances between residues with sets of distance constraints extracted from structures homologous to the evaluated model, so the higher the score the better the model.

* Selected structural model domain to build the assembly and model the whole protein.

** Model used for evaluating the impact of the variants found in this study.

Protein Domain	Initial domain position	Final domain position	Initial modelled domain position	Final modelled domain position	Modelled length	Modelling method	Template used	Evaluation				
								Molprobability Score	Verify3D	ERRAT	ProSA-Web	QMEANDisCo
NIDO	98	252	23	252	230	Modeller	No template available	-	-	-	-	-
						Robetta-AB	-	1.79	85.81	56.0606	-5.57	0.47
						CI-TASSER	-	4.19	98.06	46.25	-5.29	0.34
						AlphaFold2 *	-	1.13	100	87.7729	-5.86	0.68
VWFC	260	314	253	314	62	Modeller	No template available	-	-	-	-	-
						Robetta-AB *	-	0.83	96.36	82.6087	-4.94	0.46
						CI-TASSER	-	2.85	38.18	91.4894	-5.16	0.46
						AlphaFold2	-	1.74	71.67	65.1163	-4.65	0.47
VWFD 1	320	500	315	500	186	Modeller	7KWO_V	3.2	59.55	47.6415	-3.66	0.55
						AlphaFold2 *	-	1.39	93.84	94.697	-6.36	0.55
TIL 1	597	650	501	650	150	Modeller	7A5O_E	2.8	52.23	52.22	-2.87	0.47
						AlphaFold2 *	-	0.5	71.05	92.1348	-4.79	0.63
VWFD 2	711	886	651	886	236	Modeller	7KWO_V	3.38	80.18	21.1538	-5.2	0.55
						AlphaFold2 *	-	1.04	99.63	95.2	-6.02	0.6
TIL 2	984	1036	887	1036	150	Modeller	7A5O_E	2.8	52.83	52.2727	-2.76	0.46
						AlphaFold2 *	-	0.5	75.44	100	-6.11	0.59
VWFD 3	1098	1278	1037	1278	242	Modeller	7KWO_V	3.52	72.6	29.8578	-4.64	0.54
						AlphaFold2 *	-	0.83	97.45	96.3415	-7.33	0.65
TIL 3	1372	1425	1279	1425	147	Modeller	7A5O_E	3.12	37.04	13.6364	-2.93	0.49
						AlphaFold2 *	-	0.94	81.42	100	-5.16	0.59
VWFD 4	1485	1666	1426	1666	241	Modeller	7KWO_V, 7A5O_E	3.46	95.38	43.6364	-5.58	0.61
						AlphaFold2 *	-	1.18	93.96	89.441	-6.27	0.67
ZP	1805	2059	1667	2059	393	Modeller	6ZS5, 4WRN, 6TQL	3.49	73.73	36.3265	-5.31	0.58
						AlphaFold2 *	-	1.61	65.88	94	-9.1	0.53
Complete α -tectorin (O75443)	1	2155	1	2155	2155	AlphaFold2	-	1.52	-	89.5459	-17.6	0.57
4 Domains Assembly	98	650	23	650	628	AlphaFold2	-	1.47	90.7	83.7879	-9.1	0.6
8 Domains Assembly	98	1425	23	1425	1403	AlphaFold2	-	1.13	-	82.1324	-14.93	0.55
10 Domains Assembly **	98	2059	98	2059	1962	AlphaFold2	-	1.05	-	80.6365	-17.29	0.55

Supplementary Table 4: Probable Ca²⁺ binding sites in the α -tectorin VWFD4 protein structure.

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.18.22270926>; this version posted March 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Binding site	α -tectorin residue number	Amino acid	Score (MIB)
1	1507	ALA	2.096
	1508	ASN	2.096
2	1530	ASN	1.682
	1531	PHE	1.682
	1532	ASP	1.682
3	1624	ASN	2.143
	1626	ASN	2.143
	1627	GLY	2.099
	1628	ASP	2.143
	1630	THR	1.641
	1631	ASP	2.143
	1632	ASP	2.143
	1499	ASP	1.746
4	1664	SER	2.097
	1666	ASN	2.097

Supplementary Table 5: Predicted α -tectorin stability perturbation caused by missense variants found in this study. medRxiv preprint doi: <https://doi.org/10.1101/2022.02.18.22270926>; this version posted March 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Predictor	Variants		
	p.Cys1402Ser	p.Val1494Ala	p.Pro1790Ser
Maestro-web (kcal/mol)	Neutral (0.110)	Neutral (0.056)	Neutral (0.022)
mCSM (stability) (kcal/mol)	Destabilizing (-1.254)	Destabilizing (-1.099)	Destabilizing (-0.545)
CUPSAT thermal (kcal/mol)	Destabilizing (-13.02)	Destabilizing (-0.57)	Stabilizing (2.23)
CUPSAT denaturants (kcal/mol)	Stabilizing (12.46)	Stabilizing (0.79)	Neutral (-0.4)
DynaMut2 (kcal/mol)	Destabilizing (-0.54)	Destabilizing (-1.29)	Neutral (-0.25)
PremPS (kcal/mol)	Destabilizing (2.2)	Destabilizing (0.6)	Neutral (0.43)

Global protein stability change prediction (kcal/mol) in the α -tectorin model using different $\Delta\Delta G_{pred}$ prediction methods. For Maestro-web and PremPS, $\Delta\Delta G_{pred} < 0.0$ indicates a stabilizing mutation. On the other hand, for mCSM, CUPSAT and DynaMut2, $\Delta\Delta G_{pred} > 0.0$ indicates a stabilizing mutation. Variants were considered neutral in terms of protein stability perturbation when $-0.5 < \Delta\Delta G_{pred} < 0.5$.

SUPPLEMENTARY FIGURES

Supplementary Figure 1: Validation of candidate variants by Sanger sequencing.

Supplementary Figure 2: The four predicted Ca^{2+} binding sites in the α -tectorin VWFD4 protein structure (Supplementary Table 3, coloured in this figure in green) located near the variant Val1494Ala found in F1, F2 and a sporadic patient with MD. bioRxiv preprint doi: <https://doi.org/10.1101/2022.07.12.500000>; this version posted July 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.